By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Dividend Growth: CVS has increased its dividend by 142% over the past decade, with a current forward yield of 4.64%. This significantly surpasses the S&P 500 average of 1.35%.

The battle for supremacy in one of the fastest-growing pharmaceutical markets intensified as CVS Health will now make two drugs from Gilead Sciences - Sovaldi and Harvoni - the exclusive options ...

The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool has the following options: short October 2016 $95 puts on Celgene. The Motley Fool recommends CVS Health.

Gilead Sciences agreed to make its hepatitis C medicines the exclusive treatments for CVS Health customers, intensifying a drug-industry rivalry to win patients for the $1,000-a-day medicines.